CIK 1816307
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 81.17% | 55 |
| Unclassified | 11.29% | 5 |
| Health Care Providers & Services | 6.57% | 3 |
| Health Care Equipment & Supplies | 0.97% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | KALVISTA PHARMACEUTICALS INC | Unclassified | 6.82% | |
| 2 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 6.47% |
| 3 | COGT | Cogent Biosciences, Inc. | Health Care | 5.96% |
| 4 | CELC | Celcuity Inc. | Health Care | 4.81% |
| 5 | IMNM | Immunome Inc. | Health Care | 4.77% |
| 6 | KOD | Kodiak Sciences Inc. | Health Care | 4.46% |
| 7 | NUVL | Nuvalent, Inc. | Health Care | 4.28% |
| 8 | ABVX | Abivax S.A. | Health Care | 3.97% |
| 9 | GLUE | Monte Rosa Therapeutics, Inc. | Health Care | 3.88% |
| 10 | ERAS | Erasca, Inc. | Health Care | 3.53% |
62/67 names classified · sector 88.7% of weight · industry 88.7% · mkt cap 81.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 88.7% of the book is sector-classified (unclassified names shown, never dropped).
Only 4% of book weight classified — the grid is NOT representative of the whole book.
Classified: 4.4% of book weight (5/66 names) · unclassified 95.6%: , DNTH, COGT, CELC, IMNM, KOD, NUVL, ABVX, GLUE, ERAS +51 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | KALVISTA PHARMACEUTICALS INC | 2,876,407 | $58M | 6.8% | ADD 19% |
| 2 | DNTHDIANTHUS THERAPEUTICS INC | 654,746 | $55M | 6.5% | TRIM −13% |
| 3 | COGTCOGENT BIOSCIENCES INC | 1,314,189 | $51M | 6.0% | ADD 6% |
| 4 | CELCCELCUITY INC | 357,903 | $41M | 4.8% | TRIM −5% |
| 5 | IMNMIMMUNOME INC | 1,850,278 | $40M | 4.8% | ADD 64% |
| 6 | KODKODIAK SCIENCES INC | 991,930 | $38M | 4.5% | TRIM −3% |
| 7 | NUVLNUVALENT INC | 354,914 | $36M | 4.3% | ADD 14% |
| 8 | ABVXABIVAX SA | 302,530 | $34M | 4.0% | TRIM −28% |
| 9 | GLUEMONTE ROSA THERAPEUTICS INC | 2,002,040 | $33M | 3.9% | ADD 95% |
| 10 | ERASERASCA INC | 1,851,812 | $30M | 3.5% | ADD 41% |
| 11 | ASNDASCENDIS PHARMA A/S | 124,658 | $29M | 3.4% | ADD 153% |
| 12 | URGNUROGEN PHARMA LTD | 1,503,045 | $27M | 3.2% | TRIM −14% |
| 13 | RYTMRHYTHM PHARMACEUTICALS INC | 306,000 | $27M | 3.1% | ADD 125% |
| 14 | PRAXPRAXIS PRECISION MEDICINES I | 71,552 | $23M | 2.7% | TRIM −13% |
| 15 | ZBIOZENAS BIOPHARMA INC | 1,135,935 | $22M | 2.6% | NEW |
| 16 | SNDXSYNDAX PHARMACEUTICALS INC | 888,987 | $21M | 2.4% | ADD 38% |
| 17 | CENTESSA PHARMACEUTICALS PLC | 466,345 | $19M | 2.2% | HOLD |
| 18 | SRRKSCHOLAR ROCK HLDG CORP | 339,613 | $17M | 2.0% | NEW |
| 19 | ALKSALKERMES PLC | 460,314 | $16M | 1.9% | NEW |
| 20 | ORICORIC PHARMACEUTICALS INC | 1,100,010 | $14M | 1.6% | HOLD |
| 21 | IRONDISC MEDICINE INC | 196,028 | $13M | 1.5% | NEW |
| 22 | HLXCHELIX ACQUISITION CORP III | 1,208,986 | $12M | 1.4% | NEW |
| 23 | XENEXENON PHARMACEUTICALS INC | 197,759 | $11M | 1.4% | NEW |
| 24 | CGONCG ONCOLOGY INC | 166,349 | $11M | 1.3% | TRIM −54% |
| 25 | IMVTIMMUNOVANT INC | 414,236 | $10M | 1.2% | NEW |
| 26 | SYRESPYRE THERAPEUTICS INC | 186,618 | $9M | 1.1% | HOLD |
| 27 | BIIBBIOGEN INC | 50,967 | $9M | 1.1% | TRIM −32% |
| 28 | GHGUARDANT HEALTH INC | 98,514 | $9M | 1.1% | ADD 7% |
| 29 | PCVXVAXCYTE INC | 144,981 | $8M | 1.0% | TRIM −3% |
| 30 | SVRASAVARA INC | 1,430,982 | $8M | 0.9% | NEW |
| 31 | BNTCBENITEC BIOPHARMA INC | 717,725 | $8M | 0.9% | HOLD |
| 32 | ORKAORUKA THERAPEUTICS INC | 150,908 | $7M | 0.9% | NEW |
| 33 | CGENCOMPUGEN LTD | 3,315,845 | $7M | 0.8% | TRIM −5% |
| 34 | TRVITREVI THERAPEUTICS INC | 511,127 | $6M | 0.7% | TRIM −6% |
| 35 | INSMINSMED INC | 35,850 | $6M | 0.7% | TRIM −50% |
| 36 | VCYTVERACYTE INC | 179,700 | $6M | 0.7% | TRIM −50% |
| 37 | CERSCERUS CORP | 3,176,547 | $6M | 0.7% | ADD 13% |
| 38 | CLDXCELLDEX THERAPEUTICS INC NEW | 178,378 | $6M | 0.7% | TRIM −7% |
| 39 | CCCCC4 THERAPEUTICS INC | 1,911,785 | $5M | 0.6% | TRIM −4% |
| 40 | CYTKCYTOKINETICS INC | 71,203 | $5M | 0.6% | NEW |
| 41 | CLYMCLIMB BIO INC | 684,908 | $5M | 0.6% | NEW |
| 42 | CMPXCOMPASS THERAPEUTICS INC | 859,049 | $5M | 0.5% | TRIM −18% |
| 43 | SRZNSURROZEN INC | 144,255 | $4M | 0.5% | TRIM −8% |
| 44 | CTNMCONTINEUM THERAPEUTICS INC | 301,729 | $4M | 0.5% | HOLD |
| 45 | ZURAZURA BIO LTD | 560,651 | $3M | 0.4% | NEW |
| 46 | FULCFULCRUM THERAPEUTICS INC | 419,949 | $3M | 0.4% | ADD 6% |
| 47 | ABEOABEONA THERAPEUTICS INC | 648,942 | $3M | 0.3% | ADD 3% |
| 48 | CAMPCAMP4 THERAPEUTICS CORP | 653,594 | $3M | 0.3% | NEW |
| 49 | ANNXANNEXON INC | 496,461 | $3M | 0.3% | NEW |
| 50 | ELUTELUTIA INC | 2,498,020 | $3M | 0.3% | TRIM −9% |
| 51 | CBIOCRESCENT BIOPHARMA INC. | 130,500 | $2M | 0.3% | NEW |
| 52 | MNPRMONOPAR THERAPEUTICS INC | 43,488 | $2M | 0.3% | NEW |
| 53 | OVIDOVID THERAPEUTICS INC | 1,000,000 | $2M | 0.3% | NEW |
| 54 | NXTCNEXTCURE INC | 176,057 | $2M | 0.2% | HOLD |
| 55 | CMPSCOMPASS PATHWAYS PLC | 300,000 | $2M | 0.2% | NEW |
| 56 | NMRANEUMORA THERAPEUTICS INC. | 818,156 | $2M | 0.2% | NEW |
| 57 | SIONSIONNA THERAPEUTICS INC | 39,417 | $2M | 0.2% | TRIM −5% |
| 58 | TELATELA BIO INC | 2,259,312 | $1M | 0.2% | TRIM −15% |
| 59 | EWTXEDGEWISE THERAPEUTICS INC | 42,615 | $1M | 0.2% | HOLD |
| 60 | REPLREPLIMUNE GROUP INC | 171,936 | $1M | 0.2% | NEW |
| 61 | GENBGENERATE BIOMEDICINES INC | 100,000 | $1M | 0.1% | NEW |
| 62 | RADXRadiopharm Theranostics Ltd | 187,406 | $805,846 | 0.1% | HOLD |
| 63 | GUTSFRACTYL HEALTH INC | 1,701,625 | $779,004 | 0.1% | TRIM −83% |
| 64 | IBIOIBIO INC | 226,000 | $429,400 | 0.1% | ADD 113% |
| 65 | ADGMADAGIO MED HLDGS INC | 251,972 | $289,768 | 0.0% | TRIM −51% |
| 66 | AARDAARDVARK THERAPEUTICS INC | 33,684 | $126,989 | 0.0% | TRIM −89% |
| 67 | RCKTWWTS ROCKET PHARMACEUTICALS INC | 104,828 | $2,159 | 0.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| KALVISTA PHARMACEUTICALS INC | 612K | 1.7M | 1.8M | 1.4M | 2.4M | 2.9M | $58M |
| DNTHDIANTHUS THERAPEUTICS INC | — | 190K | 96K | 675K | 750K | 655K | $55M |
| COGTCOGENT BIOSCIENCES INC | 921K | — | — | 815K | 1.2M | 1.3M | $51M |
| CELCCELCUITY INC | — | — | — | 89K | 375K | 358K | $41M |
| IMNMIMMUNOME INC | — | — | — | — | 1.1M | 1.9M | $40M |
| KODKODIAK SCIENCES INC | 1.0M | 442K | 402K | 1.0M | 1.0M | 992K | $38M |
| NUVLNUVALENT INC | 400K | 439K | 236K | 372K | 311K | 355K | $36M |
| ABVXABIVAX SA | 285K | 211K | — | 540K | 422K | 303K | $34M |
| GLUEMONTE ROSA THERAPEUTICS INC | — | — | — | 695K | 1.0M | 2.0M | $33M |
| ERASERASCA INC | 7.5M | 7.4M | 2.6M | 1.4M | 1.3M | 1.9M | $30M |
| ASNDASCENDIS PHARMA A/S | 51K | 76K | 87K | 54K | 49K | 125K | $29M |
| URGNUROGEN PHARMA LTD | 1.1M | 1.4M | 2.0M | 1.6M | 1.7M | 1.5M | $27M |
| RYTMRHYTHM PHARMACEUTICALS INC | 274K | 338K | 401K | 370K | 136K | 306K | $27M |
| PRAXPRAXIS PRECISION MEDICINES I | 73K | 166K | 10K | 51K | 82K | 72K | $23M |
| ZBIOZENAS BIOPHARMA INC | — | — | — | — | — | 1.1M | $22M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
